Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Inks Deals to Raise A$1.8M

NEW YORK – Australian genetic testing firm Genetic Technologies said on Wednesday it has entered into definitive agreements with unnamed institutional investors for the purchase of more than 1 million American Depositary Shares at A$1.75 ($1.07) per ADS in a registered direct offering.

Each ADS represents 600 of the firm's ordinary shares, and gross proceeds from the offering, expected to close on or about April 3, is estimated at A$1.8 million ($1.1 million).

Proceeds will go toward the introduction and distribution of new products in the US, including the development of polygenic risk tests with the Translational Genomics Research Institute, and for working capital, Genetic Technologies said.

HC Wainwright is the exclusive placement agent for the offering.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.